Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Upgraded by Zacks Investment Research

Deciphera Pharmaceuticals (NASDAQ:DCPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, January 9th. The firm presently has a $28.00 price target on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 7.20% from the company’s previous close.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

Other analysts also recently issued research reports about the company. Nomura initiated coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target on the stock. Instinet initiated coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $57.00 target price on the stock. BidaskClub upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 9th. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price on the stock. Finally, Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $40.83.

Deciphera Pharmaceuticals (NASDAQ:DCPH) opened at $26.12 on Tuesday. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $28.96. The company has a market capitalization of $828.77 and a P/E ratio of -3.88.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($5.30). equities analysts predict that Deciphera Pharmaceuticals will post -2.91 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Quantitative Systematic Strategies LLC bought a new stake in Deciphera Pharmaceuticals during the fourth quarter valued at about $288,000. Kornitzer Capital Management Inc. KS grew its position in shares of Deciphera Pharmaceuticals by 84.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 211,099 shares of the company’s stock valued at $4,786,000 after purchasing an additional 96,749 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Deciphera Pharmaceuticals during the fourth quarter valued at about $636,000. Pura Vida Investments LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter valued at about $1,329,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter valued at about $1,946,000. 44.01% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Upgraded by Zacks Investment Research” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/04/deciphera-pharmaceuticals-dcph-raised-to-buy-at-zacks-investment-research.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply